Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/011988

International filing date: 15 April 2004 (15.04.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/533,103
Filing date: 29 December 2003 (29.12.2003)

Date of receipt at the International Bureau: 13 September 2004 (13.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1220764

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

September 02, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *60/486,694*
FILING DATE: *July 11, 2003*
RELATED PCT APPLICATION NUMBER: *PCT/US04/11988*

Certified by

Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

PTO/SB/16 (05-03)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request f r filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Jay	**Nelson**	**Tualitin, Oregon**

☒ *Additional inventors are being named on the **1** separately numbered sheets attached hereto*

TITLE OF THE INVENTION (500 characters max)

INHIBITION OF FLAVIVIRUS REPLICATION BY INHIBITORS OF *SRC*-FAMILY KINASES

CORRESPONDENCE ADDRESS

Direct all correspondence to:

☒ Customer Number · 22504

22504
PATENT TRADEMARK OFFICE

OR *Type Customer Number here*

☐ Firm or Individual Name	
Address	
Address	

City		State	.	ZIP	
Country		Telephone		Fax	

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification *Number of Pages* **30**   ☐ CD(s), Number _____

☒ Drawing(s) *Number of Sheets* **14**   ☒ Other (specify) **Fee Transmittal (+ copy)**

☐ Application Data Sheet. See 37 CFR 1.76   *6 sheets* Sequence Listing (printed only), Supplemental Information, Check

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ Applicant claims small entity status. See 37 CFR 1.27.

☒ A check or money order for $*80* is enclosed to cover the filing fees.

☐ The Commissioner is hereby authorized to charge filing fees to Deposit Account Number: **04-0258**

☒ The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account Number: **04-0258**

☐ Payment by credit card. Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____ .

Respectfully submitted,			
SIGNATURE .	*[signature]*	DATE	**July 11, 2003**
TYPED or PRINTED NAME	Barry L. Davison	REGISTRATION NO. *(if appropriate)*	**47,309**
TELEPHONE	**206-628-7621**	DOCKET NUMBER:	**49321-97**

	49321-97	Type a plus sign (+) inside this box →	+

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Alec	Hirsch	Portland, Oregon
Klaus	Fruh	Portland, Oregon
Victor	DeFillipis	
Jeff	King	Portland, Oregon

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

PTO/SB/17 (05-03)
Approved for use through 04/03/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995,no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($) 80

Complete if Known	
Application Number	To be assigned
Filing Date	July 10, 2003
First Named Inventor	Nelson
Examiner Name	
Art Unit	
Attorney Docket No.	49321-97

07/11/03

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ None

☒ Deposit Account:

Deposit Account Number: 04-0258

Deposit Account Name: Davis Wright Tremaine LLP

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below   ☐ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any deficiencies
to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Fee($)	Small Entity Fee Code	Fee($)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	80

SUBTOTAL (1) ($)80

2. EXTRA CLAIM FEES

	Extra Claims		Fee from below		Fee Paid
Total Claims		- 20** =		x	=
Independent Claims		- 3** =		x	=
Multiple Dependent					=

Large Entity Fee Code	Fee ($)	Small Entity Fee Code	Fee ($)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) ($)0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Fee ($)	Small Fee Code	Fee ($)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive – unavoidable	
1453	1,300	2453	650	Petition to revive – unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) ($)0

SUBMITTED BY

Name (Print/Type) **Barry L. Davison**

Signature

Registration No. Attorney/Agent **47,309**

Date **July 11, 2003**

22504
PATENT TRADEMARK OFFICE

WARNING: Information this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of

INHIBITION OF FLAVIVIRUS REPLICATION BY INHIBITORS OF *SRC*-FAMILY KINASES

5
FIELD OF THE INVENTION

The present invention relates to the novel use of inhibitors of *src*-family kinases for inhibition of flavivirus infection.

BACKGROUND

The prototypical flavivirus, yellow fever virus (YFV), was first isolated in 1927. Since

10 that time, the membership of the genus *Flavivirus* has grown to over 70 known viruses, of which more than half are associated with human disease. T hese include West Nile virus (WNV), Japanese encephalitis virus (JEV), St Louis encephalitis (SLE), and Dengue (DEN). The majority of the flaviviruses are vector borne, with approximately 50% transmitted by mosquitoes, and 30% carried by ticks. The remaining 20% are classified as "non-vector," which

15 are transmitted by an as yet unidentified vector or zoonotically from rodents or bats (for extensive review, see (1)). The general transmission cycle of the vector borne viruses involves the acquisition of the virus by the arthropod through feeding on an infected host (usually birds, small mammals, or primates). he virus replicates in the insect host, which in turn can infect an immunologically naïve bird (or small mammal or primate, depending on the virus).

20 In the case of WNV, human infection through the bite of an infected mosquito results in fever in 20 percent of cases, and 1 in 150 infections result in neurological disease. The greatest risk factor for neurological disease following infection appears to be advanced age. Treatment for WNV is supportive, there being neither a widely approved therapy available, nor a vaccine approved for use in humans, although a vaccine consisting of formalin-inactivated WNV is

25 approved for veterinary use in horses.

The flaviviruses have been sub-classified on the basis of antigenic relatedness, or more recently, on sequence similarity. Sequence information has been used to classify the viruses into 14 clades, which correlate closely with the previous antigenic classifications (2).

Epidemiology and pathology. A large number of flaviviruses are associated with human
5   disease, and the epidemiology and pathology of three of these, West Nile virus, Dengue virus, and Japanese Encephalitis virus, are briefly summarized here.

West Nile Virus (WNV) is a mosquito borne pathogen associated with fever and encephalitis. It was first identified in Uganda in 1937 (3). Although outbreaks of WNV since its discovery had been sporadic and associated with mild illness, the frequency and severity of
10   WNV disease, in horses as well as in humans, has increased since the mid 1990s (4). Outbreaks have occurred in Romania (1996), Morocco (1996), Tunisia (1997), Italy (1998), Russia (1999), Israel (1999 and 2000) and the U.S. (1999, and each summer since). The outbreak in New York in 1999 appears to mark the beginning of the spread of WNV throughout the U.S. In 1999, there were a total of 62 reported human cases isolated to the state of New York, 59 of which required
15   hospitalization. In 2000, there were 21 cases in three states, increasing to 66 cases in ten states in 2001. At the time of this writing in 2002, the CDC reports 3,580 laboratory-positive human cases over 38 states (5). If the spread of the virus is measured by the presence of infected birds or mosquitoes, the geographic extent is even greater, encompassing 43 states. It is expected that the summer of 2003 will see the virus spread further. Transmission involves cyclic transfer from
20   mosquitoes of the genus *Culex* to birds and back. Humans and horses are dead-end hosts (6).

Approximately 20% of individuals infected with WNV develop fever, as estimated by a serological survey conducted just after the 1999 New York outbreak (7). This study estimates that the total number of infections during this period was 8,200 of which 62 were reported. The fever is sometimes accompanied by weakness, nausea, headache, myalgia, arthralgia, and rash.
25   About 1 in 150 infections results in neurological disease such as encephalitis or meningitis (7, 8). Of the 59 WNV patients hospitalized in New York in 1999, 54 were diagnosed with encephalitis or meningitis; 12% of these hospitalized patients later died. In 2002, 211 of the reported cases

resulted in death (approximately a 6% fatality rate). The greatest risk factor for death is advanced age (9). There are currently no approved antiviral therapies for WNV; treatment is supportive.

  Dengue Virus (DEN). Dengue virus infects approximately 100 million people a year. It
5 is endemic in virtually all the tropic areas of the world. There are four serotypes of DEN (Dengue type 1-4). All are spread primarily by the mosquito *Aedes Aegypti,* which lives in close proximity to humans (*i.e.* a "domestic" mosquito). Unlike the case for most flaviviruses, humans are a natural host for dengue, and can produce high enough titers in the blood to continue the transmission cycle (1, 10, 11).

10   DEN infection may result in one of several syndromes (12). Dengue infection is characterized by fever, headache and rash. A more severe form, Dengue hemorrhagic fever (DHF) may include increased vascular permeability and leakage of plasma from blood vessels into tissue. Mild hemorrhage may also occur. DHF is graded on a scale of I through IV. Grade II includes greater bleeding (gum, nose, GI tract), while grades III and IV feature increased
15 vascular leakage, accompanied by loss of blood pressure and shock. Grades III and IV are also known as Dengue shock syndrome. DHF is more likely to occur when DEN infection is followed by a second infection of a different serotype. This may be due to the presence of circulating antibody that reacts with, but does not neutralize, the second infecting strain. The presence of these antibodies allows antibody-dependent enhancement of infection of
20 macrophages, which take up antibody-bound DEN via their Fc receptors. It is postulated that macrophage infection results in increased T cell activation and cytokine production, leading to severe immunopathology (13). This model does not explain, however, the relative rarity of DHF even in patients experiencing a second DEN infection, or the occasional appearance of DHF during primary DEN infection. Other theories of DHF pathogenesis include the possibility of
25 virulence factors present only in specific DEN strains or "quasispecies," or the possibility of an autoimmune response elicited by the similarity of DEN antigens to various human clotting factors (14, 15, 16).

-3-

Japanese Encephalitis Virus (JEV). JEV is endemic in much of southeast Asia, ranging from Japan and Korea at its northern range, to India in the west, and Indochina and Indonesia to the south. Sporadic cases have also been reported as far south as Papua New Guinea and Australia. Annually, there are approximately 35,000 cases and 10,000 deaths, and these figures

5 may underestimate the true toll of the disease due to incomplete surveillance and reporting. JEV is a member of an antigenic complex and clade that also include WNV. It is spread primarily by the mosquito *Culex tritaeniorhynchus*, cycling through its natural viremic hosts, pigs and birds.

Most JEV infections are sub-clinical, with only 1 in 250 infections resulting in symptoms. The primary clinical manifestation is encephalitis. After a 5-15 day incubation

10 period, symptoms begin with headache, fever, and gastrointestinal problems. These may be followed by irritability, nausea, and diarrhea with decline to generalized weakness, stupor, or coma. In children, seizures are common. 5-30% of cases are fatal.

There is no specific treatment for JEV, other than supportive care. However, vaccines do exist for JEV. These include a formalin inactivated vaccine, as well as a live attenuated strain.

15 The inactivated version has been used widely in Japan and China since the 1960s. It is also licensed for use in the U.S. and Europe for those traveling to areas in which JEV is endemic. The attenuated virus has also seen wide use in China. Both vaccines (when delivered with appropriate booster regimens) have shown efficacies greater than 90% (1, 17).

Flavivirus replication. The flaviviruses are small enveloped viruses that contain a single,

20 positive-sense RNA genome of approximately 11 kilobases (kb). The RNA is capped at its 5' end, but not 3' polyadenylated. The RNA encodes a single large open reading frame (ORF) that is processed into 10 subunits that comprise the structural components of the virion and the viral replication complex (18). The flaviviruses all possess a common organization to the coding sequence of the genome. The structural subunits are located at the 5' end. These include the

25 core (C), membrane (prM/M), and envelope (E) proteins. These are followed by the non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. NS2B and NS3 function as the serine protease that is responsible for processing much of the viral polyprotein. NS5, the

most highly conserved of the flavivirus proteins, acts as the RNA dependent RNA polymerase necessary for viral replication, and may also function as a methyltransferase that provides the genomic 5' cap. The other members of the non-structural group are largely hydrophobic and of unknown function (18).

5   Flavivirus infection of the host cell begins via attachment of the E protein to a cellular receptor. Definitive identification of a receptor for any of the flavivirus species is still absent, but glycosaminoglycans appear to be involved in the initial attachment (19). Entry of the virus into the host cell probably occurs by receptor mediated endocytosis, followed by low-pH dependent fusion of the virion with the endosome membrane, releasing the nucleocapsid and
10   genomic RNA into the cytoplasm (18, 20).

Translation of the RNA by the host cell follows, and the polyprotein is cleaved into its constituent subunits by a combination of a host cell ER resident protease and the NS2B/NS3 virally encoded serine protease. Replication of the genomic RNA occurs through a negative sense intermediate, and can be detected as early as three hours after infection in the case of YFV.
15   Flavivirus infection induces a proliferation of ER membranes in the host cell and the formation of "smooth membrane structures"- groups of vesicle-like structures in the ER lumen. The smooth membrane structures co-localize with double stranded RNA (presumably the replicative intermediate), as well as NS1 and NS3, and are believed to be the sites of RNA replication. NS2B and NS3, the constituents of the viral protease, localize to an adjacent region of induced
20   membranes (dubbed "convoluted membranes"), suggesting that polyprotein processing and NA replication are spatially separated within the infected cell (21).

Assembly and release of virions largely remains a black box. Cis-acting packaging signals in the RNA have not been identified, although the viral nucleocapsid protein C has been shown to interact with the 5' and 3' ends of the genome (22). The envelope is most likely
25   acquired by budding of the nucleocapsid precursor into the ER. At a later point in virus maturation, the prM protein is cleaved into the mature form (M) by the cellular protease furin (23). It is currently believed that prM functions to prevent the E protein from undergoing the

low pH dependent conformational change while in the cell. In agreement with this hypothesis, prevention of prM cleavage results in the release of virus particles that are less infectious than wild-type (24).

Infection of the host is thought to begin in the Langerhans cells of the skin following the

5   bite of a carrier arthropod. Viral replication continues in the regional tissue and lymph nodes, which results in the dissemination of the virus into the bloodstream. Replication then proceeds at several sites, including connective tissue, smooth muscle, liver and spleen. Neural invasion appears to occur through the olfactory epithelium in experimentally infected rodents. It is unclear if this is the primary route used by virus to gain access to the CNS in infected humans

10   (25, 26).

Treatment and vaccine development. Treatment for most flavivirus infections resulting in disease is supportive (*i.e.* fluid management, mechanical ventilation, transfusion in case of severe hemorrhage, etc.). Recent reports show efficacy of ribavirin and interferon-α2b in WNV infection, although controlled clinical trials have not been completed (8). Preventive vaccines

15   exist for YFV and JEV, both based on live, attenuated strains. Similar strategies as well as the construction of chimeric viruses based on the backbones of approved flavivirus vaccines are being used to develop vaccines against WNV, Dengue, and others (27).

There is a pronounced need in the art for novel therapeutic methods and compositions having utility for preventing or inhibiting flavivirus infection, and for treatment and/or

20   prevention of conditions related to flavivirus infection.


SUMMARY OF THE INVENTION

The present invention provides methods and compositions having utility for preventing or inhibiting flavivirus infection, and for treatment and/or prevention of conditions related to

25   flavivirus infection. Specifically, inhibitors of *src* family kinases have been shown to have said utilities. Preferably, the inventive methods and compositions are directed to inhibition of the *src* family kinase c-yes. Preferably, the flavivirus is selected from the group consisting of West Nile

-6-

virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis (SLE), and Dengue (DEN). Preferably, the flavivirus is WNV. Preferably, the *src* family kinase inhibitor is PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; Calbiochem). Preferably, the *src* family kinase inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-

5   1*H*-indole-5-sulfonic acid dimethylamide (SU6656).

Further embodiments of the present invention provide screening assays for identification of agents having therapeutic utility for preventing or inhibiting flavivirus infection, and for treatment and/or prevention of conditions related to flavivirus infection.

Particular embodiments, the present invention provide a method for the treatment of

10   flavivirus infection and related conditions, comprising administration, to a subject in need thereof, of a therapeutically effective amount of an inhibitor of a *src* family kinase, whereby at least one of flavivirus infection or related conditions are diminished relative to non-treated subjects. Preferably, the flavivirus is selected from the group consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), Dengue fever virus

15   (DEN), and combinations thereof. Preferably, the *src* family kinase is c-yes kinase.

Preferably, the inhibitor is selected from the group consisting of *src* family kinase-specific antisense RNA, *src* family kinase-specific siRNA, and a small molecule inhibitor of a *src* family kinase. Preferably, the *src* family kinase is c-yes kinase. Preferably, the inhibitor is compound having the structure of Formula I, or Formula II, or salts thereof:

20

Formula I

Formula II

Preferably, for Formula 1, R_1 is halogen, and R_2, R_3 and R_4 are independently a C1-C3 straight or branched alkyl. Preferably, Formula II, R_1 is $-SO_2N(CH_3)_2$, or $-SO_2NH_2$. Preferably, the inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). Preferably, the inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (SU6656).

Additional embodiments provide pharmaceutical compositions having utility for the treatment of flavivirus infection and related conditions, comprising a *src* family kinase inhibitor selected from the group consisting of *src* family kinase-specific antisense RNA, *src* family kinase-specific siRNA, and a small molecule inhibitor of a *src* family kinase, along with a

pharmaceutically acceptable carrier or excipient. Preferably, the *src* family kinase is c-yes

kinase. Preferably, the inhibitor is compound having the structure of Formula I, Formula II, or

salts thereof:

Formula I

5

Formula II

Preferably, for Formula I, R_1 is halogen, and wherein R_2, R_3 and R_4 are independently a

C1-C3 straight or branched alkyl. Preferably, for Formula II, R_1 is $-SO_2N(CH_3)_2$, or $-SO_2NH_2$.

Preferably, the inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-

10 d]pyrimidine (PP2).   Preferably, the inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-

ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide (SU6656).

Yet further embodiments provide a method for identification of agents having potential

therapeutic utility for the treatment of flavivirus infection and related conditions, comprising:

obtaining cells suitable to support a flavivirus infection; infecting the cells with flavivirus; contacting the infected cells with an agent that inhibits a src family kinase; and determining whether the flavivirus infection is diminished relative to control infected cells not contacted by the agent, whereby potential therapeutic agents are, at least in part, identified. Preferably, the flavivirus is selected from the group consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), Dengue fever virus (DEN), and combinations thereof. Preferably, the *src* family kinase is c-yes kinase. Preferably, the cell suitable to support flavivirus infection are selected from the group consisting of primary human hepatocellular carcinoma derived cells or cell-lines derived therefrom, Huh 7 cells, neuroblastoma cells or cell-lines derived therefrom, SKN-MC cells, and combinations thereof. Preferably, infection precedes contacting of the cells with the agent. Preferably, infection is subsequent to contacting of the cells with the agent.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows that the scr family kinase inhibitor PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) inhibits accumulation of infectious WNV in cell culture supernatants (see EXAMPLE I, below).

Figure 1B shows the effect of PP2 in inhibiting accumulation of infectious virus within infected cells. SKN-MC cells were infected with WNV as above. Infectious virus in soluble lysate was measured by plaque assay on Vero cells. Samples were collected 4 hours post addition of fresh PP2 (gray bars) and 24 hours post addition of fresh PP2 (black bars).

Figure 1C shows that levels of WNV RNA within infected SKN-MC cells did not change with PP2 addition. WNV RNA quantities were normalized to β-actin values.

Figure 2A shows reduction of c-yes mRNA in transfected Huh7 cells in response to c-yes specific siRNA. 1μg total cellular RNA was used for quantitative RT-PCR with c-yes specific primers.

Figure 2B shows WNV in siRNA treated cultures. Culture supernatant from Huh7 cells transfected with c-yes specific siRNAs (above) were harvested 24 hpi and virus measured by plaque assay on Vero cells.

Figure 3 shows K-means clusters corresponding to 238 gene with changes at any one time point post-WNV infection.

Figure 4 shows a classification by function of genes up-regulated at 15 h post-infection (hpi) in West Nile Virus cells (strain NY1999).

Figure 5 shows plots of relative gene expression, for exemplary up-regulated genes, at various hour post infection with Japanese encephalitis virus (JEV; diamond symbols), West Nile virus (WNV; square symbols) and mock infection (triangles).

Figure 6 shows the effect of tyrosine kinase inhibitors on WNV (NY1999) infection in a human hepatocellular carcinoma-derived cell line (Huh7 cells).

Figure 7 shows the effect of *src* family tyrosine kinase (SFK) inhibitors on WNV (NY1999) infection in SKN-MC neuroblastoma cells.

Figure 8 shows the amount of intracellular infectious WNV after SFK inhibitor treatment in SKN-MC cells.

Figure 9 shows the amount of intracellular WNV RNA following PP2 treatment in SKN-MC cells.

Figure 10 shows that C-yes-specific siRNA inhibits WNV replication in Huh7 cells.

DETAILED DESCRIPTION OF THE INVENTION

Overview

As stated herein above, there is currently no approved therapy to combat WNV, or other flavivirus infections. The present invention encompasses, *inter alia*, use of inhibitors of *Src*-family kinases to treat and/or prevent flavivirus infection and related conditions, based on the discovery that *Src*-family kinases, and particulary the c-yes kinase are novel therapeutic intervention targets for flavivirus infection

Additional embodiments provide therapeutic compositions useful to treat and/or prevent flavivirus infection and related conditions.

Further embodiments provide screening assays for the identification of inhibitors of *Src*-family kinases that inhibit flavivirus infection and related conditions.

Preferably, the flavivirus is selected from the group consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis (SLE), and Dengue (DEN).

Preferably, the flavivirus is WNV.

Preferably, the scr family kinase inhibitor is PP2 (see Formula I, below) (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) (Calbiochem; catalog no. 529573), or a suitable salt or derivative thereof.

Formula I

DEFINITIONS

The term "WNV" refers to West Nile virus, a flavivirus.

The term "JEV: refers to Japanese encephalitis virus, a flavivirus.

The term "SLE" refers to St. Louis encephalitis, a flavivirus.

The term "DEN" refers to Dengue, a flavivirus.

The term "PP2" (Formula I, above) refers to 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (*e.g.*, Calbiochem; catalog no. 529573).

The term "Huh7" refers to the art-recognized human hepatocellular carcinoma derived cell line.

The term "SKN-MC" refers to art-recognized neuroblastoma cells.

The term "SU6656" refers to (2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide) (*see* Blake et al., *Mol. Cell. Biol.* 20:9018-9027, Dec. 2000).

The term "SU6657" refers to (2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid amide) (*Id*).

METHODS AND COMPOSITIONS FOR INHIBITION OF FLAVIVIRUS INFECTION

According one aspect of the present invention, human hepatocellular carcinoma derived cell line Huh7 supports replication of flaviviruses, including West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV) and Dengue fever virus (DEN). The Huh7 cell line was used as a host cell model for particular embodiments described herein. Additionally, SKN-MC neuroblastoma cells were used for particular embodiments described herein.

Gene microarrays were used to define the general host cell response to flavivirus infection. Specifically, gene microarrays comprising representations of 8,100 human genes were used to compare host cell gene expression following infection with WNV, JEV, YFV and DEN. For WNV, K-means clusters corresponding to 238 genes having changes in expression at any one time point post-WNV infection are shown in Figure 3.

Likewise, microarray results with JEV showed greater than 100 host genes whose expression was increased by between 2- and 10-fold at 15 h post-infection (hpi). Additionally, quantitative RT-PCR (Taqman) was used to show that several of these genes are also up-regulated in Huh7 cells during WNV infection (e.g., at 15 hpi).

Figure 4 shows a classification by function of genes up-regulated at 15 h post-infection (hpi) in West Nile Virus. Analysis of the up-regulated genes revealed that they include components of a signal transduction cascade that signals through a member of the src-family tyrosine kinase family (Figures 4 and 5).

Figure 5 shows plots of the observed relative gene expression, for exemplary up-regulated genes, at various times (hours) post-infection with Japanese encephalitis virus (JEV; diamond symbols), West Nile virus (WNV; square symbols) and mock infection (triangles).

Significantly, for example, as shown in EXAMPLE 1 below, the addition of a specific inhibitor of src-family kinases, to Huh7 cells at the time of WNV infection resulted in a dose-dependent reduction of virus recovered from the culture supernantant, as measured by plaque

assay and quantitative RT-PCR of viral RNA (up to 90%, as compared to control samples). Inhibition of src-family kinase, however, did not result in a corresponding reduction of viral RNA found within the infected cells, indicating that this pathway (*i.e.*, src family kinases, and related signal transduction) plays a role in viral assembly or egress from the host cell.

5   Likewise, src-family kinases can be inhibited by antisense, ribozymes, and siRNA.

siRNA

The invention, in particular aspects, contemplates introduction of RNA with partial or fully double-stranded character into the cell or into the extracellular environment. Inhibition is

10   specific to the *src* family kinase expression in that a nucleotide sequence from a portion of the target *src* family kinase gene is chosen to produce inhibitory RNA. This process is effective in producing inhibition (partial or complete), and is kinase gene-specific. In particular embodiments, the target cell containing the target *src* family kinase gene may be a human cell subject to infection by flaviviruses, or transformed cells (*e.g.*, hepatocellular carcinoma cells or

15   cell-lines derived therefrom, neuroblastoma cells or cell-lines derived therefrom). Methods of preparing and using RNAi are generally disclosed in U.S. Patent 6,506,559, incorporated herein by reference.

The RNA may comprise one or more strands of polymerized ribonucleotide, and may include modifications to either the phosphate-sugar backbone or the nucleoside. For example,

20   the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications in RNA structure may be tailored to allow specific genetic inhibition while avoiding a general panic response in some organisms which is generated by dsRNA. Likewise, bases may be modified to block the activity of adenosine deaminase. RNA may be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide

25   can be introduced by *in vitro* enzymatic or organic synthesis.

The double-stranded structure may be formed by a single self-complementary RNA strand or two complementary RNA strands. RNA duplex formation may be initiated either inside

or outside the cell. The RNA may be introduced in an amount which allows delivery of at least

one copy per cell. Higher doses of double-stranded material may yield more effective inhibition.

Inhibition is sequence-specific in that nucleotide sequences corresponding to the duplex region

of the RNA are targeted for genetic inhibition. NA containing a nucleotide sequence identical to

5   a portion of the *src* family kinase target gene is preferred for inhibition. RNA sequences with

insertions, deletions, and single point mutations relative to the target sequence have also been

found to be effective for inhibition. Sequence identity may be optimized by alignment

algorithms known in the art and calculating the percent difference between the nucleotide

sequences. Alternatively, the duplex region of the RNA may be defined functionally as a

10   nucleotide sequence that is capable of hybridizing with a portion of the target gene transcript.

RNA may be synthesized either *in vivo* or *in vitro*. Endogenous RNA polymerase of the

cell may mediate transcription in vivo, or cloned RNA polymerase can be used for transcription

in vivo or *in vitro*. For transcription from a transgene in vivo or an expression construct, a

regulatory region may be used to transcribe the RNA strand (or strands).

15   For RNAi, the RNA may be directly introduced into the cell (*i.e.*, intracellularly); or

introduced extracellularly into a cavity, interstitial space, into the circulation of an organism,

introduced orally, or may be introduced by bathing an organism in a solution containing RNA.

Methods for oral introduction include direct mixing of RNA with food of the organism, as well

as engineered approaches in which a species that is used as food is engineered to express an

20   RNA, then fed to the organism to be affected. Physical methods of introducing nucleic acids

include injection directly into the cell or extracellular injection into the organism of an RNA

solution.

Inhibition of gene expression refers to the absence (or observable decrease) in the level of

protein and/or mRNA product from a *src* family kinase target gene. Specificity refers to the

25   ability to inhibit the target gene without manifest effects on other genes of the cell. The

consequences of inhibition can be confirmed by examination of the outward properties of the cell

or organism or by biochemical techniques such as RNA solution hybridization, nuclease

protection, Northern hybridization, reverse transcription, gene expression monitoring with a microarray, antibody binding, enzyme linked immunosorbent assay (ELISA), Western blotting, radioimmunoassay (RIA), other immunoassays, fluorescence activated cell analysis (FACS), and flavivirus viral infection as described herein. For RNA-mediated inhibition in a cell line or whole organism, gene expression is conveniently assayed by use of a reporter or drug resistance gene whose protein product is easily assayed. Many such reporter genes are known in the art.

For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications in RNA structure may be tailored to allow specific genetic inhibition while avoiding a general panic response in some organisms which is generated by dsRNA. Likewise, bases may be modified to block the activity of adenosine deaminase. RNA may be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide can be introduced by *in vitro* enzymatic or organic synthesis.

RNA containing a nucleotide sequences identical to a portion of the *src* family kinase target gene are preferred for inhibition. RNA sequences with insertions, deletions, and single point mutations relative to the target sequence may be effective for inhibition. Thus, sequence identity may optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters *(e.g.,* University of Wisconsin Genetic Computing Group). Greater than 90% sequence identity, or even 100% sequence identity, between the inhibitory RNA and the portion of the *src* family kinase target gene is preferred. Alternatively, the duplex region of the RNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the *src* family kinase target gene transcript *(e.g.,* 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C. or 70°C. hybridization for 12-16 hours; followed by washing). The length of the identical nucleotide sequences may be at least 25, 50, 100, 200, 300 or 400 bases.

A 100% sequence identity between the RNA and the *src* family kinase target gene is not required to practice the present invention. Thus the methods have the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence.

5   *src* family kinase RNAi may be synthesized by art-recognized methods either *in vivo* or *in vitro*. Endogenous RNA polymerase of the cell may mediate transcription *in vivo*, or cloned RNA polymerase can be used for transcription in vivo or in vitro. For transcription from a transgene *in vivo* or an expression construct, a regulatory region (e.g., promoter, enhancer, silencer, splice donor and acceptor, polyadenylation) may be used to transcribe the RNA strand

10   (or strands). Inhibition may be targeted by specific transcription in an organ, tissue, or cell type; stimulation of an environmental condition (*e.g.*, infection, stress, temperature, chemical inducers); and/or engineering transcription at a developmental stage or age. The RNA strands may or may not be polyadenylated; the RNA strands may or may not be capable of being translated into a polypeptide by a cell's translational apparatus.

15   RNA may be chemically or enzymatically synthesized by manual or automated reactions. The RNA may be synthesized by a cellular RNA polymerase or a bacteriophage RNA polymerase (e.g., T3, T7, SP6). The use and production of an expression construct are known in the art (for example, WO 97/32016; U.S. Pat. Nos. 5,593,874, 5,698,425, 5,712,135, 5,789,214, and 5,804,693; and the references cited therein). If synthesized chemically or by in vitro

20 enzymatic synthesis, the RNA may be purified prior to introduction into the cell. For example, RNA can be purified from a mixture by extraction with a solvent or resin, precipitation, electrophoresis, chromatography, or a combination thereof. Alternatively, the RNA may be used with no or a minimum of purification to avoid losses due to sample processing. The RNA may be dried for storage or dissolved in an aqueous solution. The solution may contain buffers or

25 salts to promote annealing, and/or stabilization of the duplex strands.

        RNA may be directly introduced into the cell (*i.e.*, intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced

orally, or may be introduced by bathing an organism in a solution containing the RNA. Methods for oral introduction include direct mixing of the RNA with food of the organism, as well as engineered approaches in which a species that is used as food is engineered to express the RNA, then fed to the organism to be affected. For example, the RNA may be sprayed onto a plant or a

5   plant may be genetically engineered to express the RNA in an amount sufficient to kill some or all of a pathogen known to infect the plant. Physical methods of introducing nucleic acids, for example, injection directly into the cell or extracellular injection into the organism, may also be used. Vascular or extravascular circulation, the blood or lymph system, and the cerebrospinal fluid are sites where the RNA may be introduced. A transgenic organism that expresses RNA

10   from a recombinant construct may be produced by introducing the construct into a zygote, an embryonic stem cell, or another multipotent cell derived from the appropriate organism.

Physical methods of introducing nucleic acids include injection of a solution containing the RNA, bombardment by particles covered by the RNA, soaking the cell or organism in a solution of the RNA, or electroporation of cell membranes in the presence of the RNA. A viral

15   construct packaged into a viral particle would accomplish both efficient introduction of an expression construct into the cell and transcription of RNA encoded by the expression construct. Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, such as calcium phosphate, and the like. Thus the RNA may be introduced along with components that perform one or more of the

20   following activities: enhance RNA uptake by the cell, promote annealing of the duplex strands, stabilize the annealed strands, or other-wise increase inhibition of the target gene.

The RNAi may be used alone or as a component of a kit having at least one of the reagents necessary to carry out the in vitro or in vivo introduction of RNA to test samples or subjects. Preferred components are the dsRNA and a vehicle that promotes introduction of the

25   dsRNA. Such a kit may also include instructions to allow a user of the kit to practice the invention.

Suitable injection mixes are constructed so animals receive an average of 0.5×10^6 to 1.0×10^6 molecules of RNA. For comparisons of sense, antisense, and dsRNA activities, injections are compared with equal masses of RNA (*i.e.*, dsRNA at half the molar concentration of the single strands). Numbers of molecules injected per adult are given as rough approximations

5   based on concentration of RNA in the injected material (estimated from ethidium bromide staining) and injection volume (estimated from visible displacement at the site of injection). A variability of several-fold in injection volume between individual animals is possible.

EXAMPLE 1

10   (*src* family kinase inhibitors resulted in a substantial decrease of infectious WNV)

DNA Microarray analysis

Methods. Viral stocks for all microarray infections were grown on Vero cells. Viral titers were determined by limiting dilution on Veros. In order to avoid effects from cytokines present in viral stocks, the virus was concentrated and purified before infection of target cells.

15   Approximately 28 ml of stock was underlayed with 7 ml of 20% sorbitol cushion and spun for 1.5 h at 25,000 rpm ($113,000 \times g$) and 20°C in an SW28 rotor (Beckman). The virus pellet was resuspended in Dulbecco's modified Eagle medium (DMEM) supplemented with 0.1% bovine serum albumin (BSA). Approximately 3×10^6 Huh7 cells were infected at a multiplicity of 10 with the concentrated virus stock. At 0.5h, 2h, 5h, 10h, 15h, 20h and 26h post-infection,

20   duplicate plates were collected and RNA isolated by TRIzol reagent (Invitrogen) according to manufacturer's instructions. Labled cDNA was generated from the total RNA and hybridized to cDNA spotted arrays. The spotted arrays contained cDNAs representing almost 8400 genes. Approximately 200 genes were identified as having increased expression in both JEV and WNV infected Huh7 cells at the 15 hour time point.

25   *Confirmation of microarray results.* Quantitative real-time RT-PCR analysis was performed on RNA samples harvested from independent infections of Huh7 cells with JEV or WNV, to confirm the results of the initial microarray experiment. As shown in Figures 5A or

5B, four of the genes reported to be upregulated at 15 h by the spotted array experiment are confirmed by RT-PCR analysis. RT-PCR was performed using Omniscript reverse transcriptase (Qiagen) and random hexamer primers, followed by PCR in an ABI Prism 7700 Sequence Detector using gene specific primers in the presence of SYBR green (Applied Biosystems). Interestingly, and in agreement with the array results, the upregulation seems to be a transient event that occurs at approximately 15 h post infection, but is absent by 24 h post infection.

Addition of the *src* family kinase inhibitor PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; *e.g.*, Calbiochem; catalog no. 529573) at 20 µM to WNV infected SKN-MC neuroblastoma cells resulted in a 30-fold decrease of infectious WNV in the supernatant 22 hours post-infection (20 h post-PP2 addition) (Figure 1A, and Figure 7). Similar results were obtained using Huh7 cells (Figure 6).

Specifically, Figure 1A shows that PP2 inhibits accumulation of infectious WNV in cell culture supernatants. SKN-MC neutoblastoma cells were infected with WNV at a multiplicity of 5. Two (2) hours post-infection (hpi, cells were treated with PP2 to a final concentration of 20 µM, or DMSO only as a control. Culture supernatant was harvested 20 hours post-infection, and virus was measured by plaque assay on Vero cells. Likewise, Figure 7 shows the observed effect of *src* family tyrosine kinase (SFK) inhibitors on WNV (NY1999) infection in SKN-MC neuroblastoma cells.

Figure 6 shows the observed effect of tyrosine kinase inhibitors on WNV (NY1999) infection in a human hepatocellular carcinoma-derived cell line (Huh7 cells).

Additionally, infectious virus *within* infected cell lysates was decreased almost 10^6-fold four hours post-addition of PP2 (Figure 1B, gray bars; and Figure 8).

Figure 1B shows the effect of PP2 in inhibiting accumulation of infectious virus within infected cells. Specifically, SKN-MC cells were infected with WNV as above. At 2 hpi, cells were treated with PP2 at the indicated final concentrations. At 20 hpi, cells were re-fed with media containing fresh PP2 at the same concentration. Cells were washed 3-times with phosphate buffered saline (PBS), resuspended in 250 µl PBS, and then lysed by 3 successive

freeze/thaws. Lysates were centrifuged at 13,000 x g for 5 minutes, followed by collection of the supernatant. Infectious virus in soluble lysate was measured by plaque assay on Vero cells. Samples were collected 4-hours post-addition of fresh PP2 (gray bars) and 24 hours post addition of fresh PP2 (black bars). 24-hours post-addition of PP2, virus within the infected cell was

5 approximately 500-fold lower, indicating some recovery from the effect of the drug (Fig. 1B, black bars). Figure 8 shows the amount of intracellular infectious WNV after SFK inhibitor treatment in SKN-MC cells.

Quantification of viral RNA within infected cells (4 hours post PP2 addition) showed no significant difference between treated or untreated cells (Figure 1C; and Figure 9), suggesting

10 that the effect of the inhibitor is exerted at a post-viral RNA replication stage.

Figure 1C shows that levels of WNV RNA within infected SKN-MC cells did not change with the addition of PP2. Specifically, cells were prepared as described above in relation to Figure 1B. Four hours post fresh PP2 addition, RNA was isolated from 200 μl of cell lysate by Trizol reagent (Invitrogen), and 1 μg total RNA was used in a quantitative RT-PCR reaction

15 (Taqman) using WNV-specific primer and probe set and standards. An additional RT-PCR was performed using β-actin-specific primers and probe, for an internal control. WNV RNA quantities were normalized to the β-actin values. Figure 9 shows the amount of intracellular WNV RNA following PP2 treatment in SKN-MC cells.

Additionally, in Huh7 hepatocellular carcinoma cells, transfection of siRNA designed to

20 inhibit production of c-yes, but not a control siRNA (lamin A/C) resulted in an approximately 8-fold reduction of the amount of WNV in the culture supernatant (Figures 2A and B; and Figure 10).

Specifically, Figure 2A shows the observed reduction of c-yes mRNA in response to c-yes-specific siRNA. Huh7 cells were transfected with either of c-yes-specific siRNAs 214 or

25 316, or a control siRNA directed against Lamins A and C. Transfection of 300,000 cells was carried out with 2 μl of a 20 μM siRNA (Dharmacon) and 1 μl Oligofectamine (Invitrogen) according to the manufacturer's protocol. Cells were transfected 24 hours post-transfection, and

cells and supernatant harvested at 24 hpi. 1 μg total cellular RNA was used for quantitative RT-PCR with c-yes-specific primers.

Figure 2B shows the measured levels of WNV in the siRNA treated cultures. Culture supernatant from Huh7 cells transfected with c-yes specific siRNAs (above) were harvested 24 hpi, and virus was measured by plaque assay on Vero cells.

Figure 10 shows that C-yes-specific siRNA inhibits WNV replication in Huh7 cells.

These results identify and validate c-yes as a *src*-family kinase therapeutic target for the treatment of flavivirus and related conditions, and indicates that PP2 may exert its effect on flavivirus infection, at least in part, through this target.

At 24 hours post-addition of PP2 (Figure 2B; and Figure 8), intracellular levels of WNV have recovered somewhat relative to untreated cells.

According to the present invention, inhibitors with longer effective half-lives have a longer period of WNV inhibition.

LITERATURE CITED

1. Burke, D. S., and T. P. Monath 2001. Flaviviruses, p. 1043-1125. In D. M. Knipe, and P. M. Howley (eds), Knipe, D. M. Howley, P. M., Fourth ed. Lippincott Williams & Wilkins, Philadelphia.

2. Kuno, G., G. J. Chang, K. R. Tsuchiya, N. Karabatsos, and C. B. Cropp 1998. Phylogeny of the genus Flavivirus J Virol. 72:73-83.

3. Smithburn, K. C., T. P. Hughes, A. W. Burke, and J. H. Paul 1940. A neurotropic virus isolated from the blood of a native of Uganda American Journal of Tropical Medicine. 20:471-92.

4. Petersen, L. R., and J. T. Roehrig 2001. West Nile virus: a reemerging global pathogen Emerg Infect Dis. 7:611-4.

5. Anonymous 2002, posting date. West Nile Virus. Centers for Disease Control. [Online.]

6.   Campbell, G. L., A. A. Marfin, R. S. Lanciotti, and D. J. Gubler 2002. West Nile virus Lancet Infect Dis. 2:519-29.

7.   Mostashari, F., M. L. Bunning, P. T. Kitsutani, D. A. Singer, D. Nash, M. J. Cooper, N. Katz, K. A. Liljebjelke, B. J. Biggerstaff, A. D. Fine, M. C. Layton, S. M. Mullin, A. J. Johnson, D. A. Martin, E. B. Hayes, and G. L. Campbell 2001. Epidemic West Nile encephalitis, New York, 1999: results of a household- based seroepidemiological survey Lancet. 358:261-4.

8.   Petersen, L. R., and A. A. Marfin 2002. West Nile virus: a primer for the clinician Ann Intern Med. 137:173-9.

9.   Nash, D., F. Mostashari, A. Fine, J. Miller, D. O'Leary, K. Murray, A. Huang, A. Rosenberg, A. Greenberg, M. Sherman, S. Wong, and M. Layton 2001. The outbreak of West Nile virus infection in the New York City area in 1999 N Engl J Med. 344:1807-14.

10.   Gibbons, R. V., and D. W. Vaughn 2002. Dengue: an escalating problem Bmj. 324:1563-6.

11.   Solomon, T., and M. Mallewa 2001. Dengue and other emerging flaviviruses J Infect. 42:104-15.

12.   McBride, W. J., and H. Bielefeldt-Ohmann 2000. Dengue viral infections; pathogenesis and epidemiology Microbes Infect. 2:1041-50.

13.   Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology Science. 239:476-81.

14.   Bielefeldt-Ohmann, H. 1997. Pathogenesis of dengue virus diseases: missing pieces in the jigsaw Trends Microbiol. 5:409-13.

15.   Leitmeyer, K. C., D. W. Vaughn, D. M. Watts, R. Salas, I. Villalobos, C. de, C. Ramos, and R. Rico-Hesse 1999. Dengue virus structural differences that correlate with pathogenesis J Virol. 73:4738-47.

16.   Markoff, L. J., B. L. Innis, R. Houghten, and L. S. Henchal 1991. Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection J Infect Dis. 164:294-301.

17.   Tsai, T. F., G. J. Chang, and Y. X. Yu 1999. Japanese Encephalitis Vaccines, p. 672-710. In S. A. Plotkin, and W. A. Orenstein (eds), Vaccines. W.B. Saunders Comapany, Philadelphia.

18.   Lindenbach, B. D., and C. M. Rice 2001. Flaviviridae: The Viruses and Their Replication, p. 991-1041. In D. M. Knipe, and P. M. Howley (eds), c, Fourth ed. Lippincott Williams & Wilkins, Philadelphia.

19.   Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate Nat Med. 3:866-71.

20.   Kuhn, R. J., W. Zhang, M. G. Rossmann, S. V. Pletnev, J. Corver, E. Lenches, C. T. Jones, S. Mukhopadhyay, P. R. Chipman, E. G. Strauss, T. S. Baker, and J. H. Strauss 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion Cell. 108:717-25.

21.   Westaway, E. G., J. M. Mackenzie, M. T. Kenney, M. K. Jones, and A. A. Khromykh 1997. Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus- induced membrane structures J Virol. 71:6650-61.

22.   Khromykh, A. A., and E. G. Westaway 1996. RNA binding properties of core protein of the flavivirus Kunjin Arch Virol. 141:685-99.

23.   Stadler, K., S. L. Allison, J. Schalich, and F. X. Heinz 1997. Proteolytic activation of tick-borne encephalitis virus by furin J Virol. 71:8475-81.

24.   Heinz, F. X., and S. L. Allison 2000. Structures and mechanisms in flavivirus fusion Adv Virus Res. 55:231-69.

- 24 -

25.   McMinn, P. C., L. Dalgarno, and R. C. Weir 1996. A comparison of the spread of Murray Valley encephalitis viruses of high or low neuroinvasiveness in the tissues of Swiss mice after peripheral inoculation Virology. 220:414-23.

26.   Monath, T. P., C. B. Cropp, and A. K. Harrison 1983. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy Lab Invest. 48:399-410.

27.   Monath, T. P. 2001. Prospects for development of a vaccine against the West Nile virus Ann N Y Acad Sci. 951:1-12.

CLAIMS

We Claim:

1.   A method for the treatment of flavivirus infection and related conditions, comprising administration, to a subject in need thereof, of a therapeutically effective amount of an inhibitor of a *src* family kinase, whereby at least one of flavivirus infection or related conditions are diminished relative to non-treated subjects.

2.   The method of claim 1, wherein the flavivirus is selected from the group consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), Dengue fever virus (DEN), and combinations thereof.

3.   The method of claim 1, wherein the *src* family kinase is c-yes kinase.

4.   The method of claim 1, wherein the inhibitor is selected from the group consisting of *src* family kinase-specific antisense RNA, *src* family kinase-specific siRNA, and a small molecule inhibitor of a *src* family kinase.

5.   The method of claim 4, wherein, the *src* family kinase is c-yes kinase.

6.   The method of any one of the preceding claims, wherein the inhibitor is compound having the structure of Formula I, or Formula II, or salts thereof:


Formula I

R₁

R_1

Formula II

7.   The method of claim 6, wherein for Formula 1, R_1 is halogen, and R_2, R_3 and R_4 are independently a C1-C3 straight or branched alkyl.

8.   The method of claim 6, wherein for Formula II, R_1 is $-SO_2N(CH_3)_2$, or $-SO_2NH_2$.

9.   The method of claim 6, wherein the inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

10.   The method of claim 6, wherein the inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide (SU6656).

11.   A pharmaceutical composition having utility for the treatment of flavivirus infection and related conditions, comprising a *src* family kinase inhibitor selected from the group consisting of *src* family kinase-specific antisense RNA, *src* family kinase-specific siRNA, and a small molecule inhibitor of a *src* family kinase, along with a pharmaceutically acceptable carrier or excipient.

12.   The pharmaceutical composition of claim 11, wherein the *src* family kinase is c-yes kinase.

13.   The pharmaceutical composition of claim 11, wherein the inhibitor is compound having the structure of Formula I, Formula II, or salts thereof:

Formula I

Formula II

14. The composition of claim 13, wherein, for Formula I, R_1 is halogen, and wherein R_2, R_3 and R_4 are independently a C1-C3 straight or branched alkyl.

15. The composition of claim 13, wherein for Formula II, R_1 is $-SO_2N(CH_3)_2$, or $-SO_2NH_2$.

16. The composition of claim 13, wherein the inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

17. The composition of claim 13, wherein the inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (SU6656).

18. A method for identification of agents having potential therapeutic utility for the treatment of flavivirus infection and related conditions, comprising: .

-obtaining cells suitable to support a flavivirus infection;

-infecting the cells with flavivirus;

-contacting the infected cells with an agent that inhibits a src family kinase; and

-determining whether the flavivirus infection is diminished relative to control infected

5   cells not contacted by the agent, whereby potential therapeutic agents are, at least in part,

identified.

19.   The method of claim 18, wherein the flavivirus is selected from the group

consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus

(YFV), Dengue fever virus (DEN), and combinations thereof.

10   20.   The method of claim 18, wherein the *src* family kinase is c-yes kinase.

21.   The method of claim 18, wherein the cell suitable to support flavivirus infection

are selected from the group consisting of primary human hepatocellular carcinoma derived cells

or cell-lines derived therefrom, Huh 7 cells, neuroblastoma cells or cell-lines derived therefrom,

SKN-MC cells, and combinations thereof.

15   22.   The method of claim 18, wherein infection precedes contacting of the cells with

the agent.

23.   The method of claim 18, wherein infection is subsequent to contacting of the cells

with the agent.

ABSTRACT OF THE DISCLOSURE

Gene microarrays were used to identify cellular genes having up-regulated expression following infection with flaviviruses, including West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV) and Dengue fever virus (DEN). The up-regulated genes include those corresponding to components of a signal transduction cascade that signals through a member of the src-family tyrosine kinase family. The addition of specific inhibitors of *src*-family kinases, to Huh7 cells at the time of WNV infection resulted in a substantial dose-dependent reduction of virus recovered from the culture supernatant. Particular embodiments of the present invention provide for therapeutic methods and compositions for the treatment of flavivirus infection and related conditions. Additional embodiments provide screening assays for therapeutic agents having utility for the treatment of flavivirus infection and related conditions.

Fig. 1A

Fig. 1B

Fig. 1C

Fig. 2A

Fig. 2B

K-means clusters of 238 genes with changes at any one time point post WNV(NY1999) infection

Fig. 3

Function of genes up at 15 hours

Number Total Genes : 93
Number Total Genes with GO at level 2 and molecular_function: 71
Number Total Genes without GO at this level and type: 2
Number Total Genes without GO: 20

Gene Ontology Term	
binding	43.01%
enzyme	34.41%
signal transducer	11.83%
transporter	8.60%
b lete	7.53%
translation regulator	6.45%
tructural molecule	5.38%
transcription regulator	5.38%
enzyme regulator	3.23%
molecular_function unknown	2.15%
chap rone	1.08%
lysin	1.08%
motor	1.08%
GO Term presents in other levels	2.15%

Fig. 4

Fig. 5A

Fig. 5 B

Effect of tyrosine kinase inhibitors on WNV
(NY1999) infection in Huh7 cells

Fig. 6

•24 hpi; MOI=1

Effect of src family tyrosine kinase inhibitors on WNV infection in SKN-MC neuroblastoma cells

Legend:
- 24 hpI, 4 h post SU6656
- 28 hpI, 8 h post SU6656

Left panel x-axis: DMSO, 20 μM PP2
Left panel y-axis: 0, 0.2, 0.4, 0.6, 0.8, 1, 1.2

Right panel x-axis: DMSO, 5 μM SU6656, 20 μM SU6656
Right panel y-axis: 0, 0.2, 0.4, 0.6, 0.8, 1, 1.2

Fig. 7

Intracellular infectious WNV after SFK inhibitor treatment

Fig. 8

Intracellular WNV RNA following PP2 treatment

Fig. 9

C-yes specific siRNA inhibits WNV replication

Supernatant WNV

4.0E+07
3.5E+07
3.0E+07
2.5E+07
2.0E+07
1.5E+07
1.0E+07
5.0E+06
0.0E+00

1 ul ofn +WNV   c-yes 214+WNV   c-yes 316 +WNV   Lamin A/C +WNV

c–Yes mRNA

1.2
1
0.8
0.6
0.4
0.2
0

1 ul ofn +WNV   c-yes 214+WNV   c-yes 316 +WNV   Lamin A/C +WNV

Fig. 10

•24 h post infection; 72h post si RNA transfection

CALBIOCHEM®

PP2

Size

Cat. No.   529573

1 mg

Synonym:	4-Amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-d]pyrimidine

Description: A potent and selective inhibitor of the *src* family of tyrosine kinases similar to PP1. Selectively inhibits p56[lck] (IC$_{50}$ = 4 nM), p59[fynT] (IC$_{50}$ = 5 nM), and Hck (IC$_{50}$ = 5 nM) compared to other tyrosine kinases, such as EGF-R (IC$_{50}$ = 480 nM), JAK2 (IC$_{50}$ >50 μM) or ZAP-70 (IC$_{50}$ >100 μM). Also potently inhibits anti-CD3-stimulated tyrosine phosphorylation of human T cells (IC$_{50}$ = 600 nM).

Form: Pale purple solid. Packaged under an inert gas.

Molecular Weight: 301.8

Molecular Formula: $C_{15}H_{16}ClN_5$

Structure:

Purity: ≥95% by HPLC

Solubility: DMSO. Further dilute with aqueous buffers just prior to use.

Storage: Freezer (-20°C). Following reconstitution, store in the refrigerator (+4°C). This product is stable for 3 years as supplied. Stock solutions are stable for several months at +4°C.

Reference: Hanke, J.H., et al. 1996. *J. Biol. Chem.* **271**, 695.

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR DRUG USE.

CALBIOCHEM®

10394 Pacific Center Court
San Diego, CA 92121
(619) 450-9600

Customer Service: (800) 854-3417
Technical Service: (800) 628-8470
Fax: (800) 776-0999

Protein Tyrosine Kinase Inhibitors

Protein tyrosine kinases mediate the transduction and processing of many extra- and intracellular signals. They are critical in regulating cell growth and differentiation and are deeply involved in oncogenesis. There are two general classes of protein tyrosine kinases: the receptor tyrosine kinases and the receptor-associated tyrosine kinases. The receptor tyrosine kinases possess an extracellular ligand binding domain and an intracellular catalytic domain with intrinsic tyrosine kinase activity.

Binding of a ligand to the receptor leads to a variety of downstream effects including stimulation of other tyrosine kinases, elevation of intracellular calcium levels, activation of serine/threonine kinases, phospholipase C and phosphatidylinositol-3'-kinase, and ultimately changes in gene expression.[1] Many substrates for protein tyrosine kinases contain a structural motif, Src homology 2 domain (SH2), that binds to phosphotyrosine residues and mediates the interaction of substrates with activated protein tyrosine kinases.[2,3] A model pathway leading to the activation of the MAP kinase cascade is depicted in the figure.

The ligand binds to the receptor tyrosine kinase (RTK) triggering receptor dimerization and autophosphorylation. Grb2 binds to the activated receptor via its SH2 domain and to Sos via its SH3 domain(s). Sos stimulates GDP-GTP exchange on Ras, activating a cascade of Ser/Thr kinases that ultimately leads to changes in gene expression.

The receptor-associated tyrosine kinases transmit signals from the membrane by interacting with the cytoplasmic domain of membrane proteins. One of the better characterized examples of this is the involvement of Lck in signaling through the T-cell receptor.[4]

The design of specific inhibitors of tyrosine kinases is important both for fundamental research and for developing therapeutic strategies for the treatment of disorders such as cancer, atherosclerosis, psoriasis, and septic shock in which increased tyrosine kinase activity has been reported.[5-7] Two classes of protein tyrosine kinase inhibitors have been developed. One acts by binding to the ATP binding site and the other by binding to the substrate binding site of the enzyme.

Among the inhibitors that act at the ATP binding site, genistein is the most commonly used. One drawback of this class of inhibitors is that they exhibit greater cytotoxicity and cause non-specific inhibition of serine/threonine kinases.[8]

Gazit and others have developed a series of synthetic compounds, tyrphostins, (also known as AG compounds), that inhibit protein tyrosine kinases by binding to the substrate binding site.[9-11] They structurally resemble tyrosine and erbstatin moieties and have hydrophobic characteristics which allow them to readily traverse the cell membrane. Many of the tyrphostins have selective and distinct inhibitory activities in various tyrosine kinase assay systems.

Cited References:
1. Medema, R.H., and Bos, J.L. 1993. *Crit. Rev. Oncology* 4, 615.
2. Koch, C.A., et al. 1991. *Science* 252, 668.
3. Smithgall, T.E. 1995. *J. Pharmacol. Toxicol. Methods* 34, 125.
4. Rudd, C.E., et al. 1988. *Proc. Natl. Acad. Sci. USA* 85, 5190.
5. Levitzki, A., and Gazit, A. 1995. *Science* 267, 1782.
6. Weinstein, S. L., et al. 1991. *Proc. Natl. Acad. Sci. USA* 88, 4148.
7. Ross, R. 1993. *Nature* 362, 801.
8. Levitzki, A. 1990. *Biochem. Pharm.* 40, 913.
9. Gazit, A., et al. 1989. *J. Med. Chem.* 32, 2344.
10. Gazit, A., et al. 1991. *J. Med. Chem.* 34, 1896.
11. Nowak, F., et al. 1997. *Biochem. Pharmacol.* 53, 287.

Please call our Technical Service Department or your local sales office for more information on these products.

Search:

Product Name

Advanced Search

| My Account | Products | Technical Resources | What's New | About Us | Contact Us |

New Products | Ordering Help | Browse Products | Product Spotlight

Products

Quick Order | Items: 0

Protein Kinases » Protein Kinase Inhibitors » Protein Tyrosine Kinase (PTK) Inhibitors

PP2

Cat. No. 529573

Tech Resources

•Product Data Sheet

•Technical Bulletin

Store/Ship

See Key

Also available in:

BULK!

AG 1879
4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine

Off-white solid. PACKAGED UNDER INERT GAS. A potent and selective inhibitor of the Src family of protein tyrosine kinases. Inhibits p56^{lck} (IC$_{50}$ = 4 nM), p59^{fynT} (IC$_{50}$ = 5 nM), and Hck (IC$_{50}$ = 5 nM). Does not significantly affect the activity of EGFR kinase (IC$_{50}$ = 480 nM), JAK2 (IC$_{50}$ > 50 µM), or ZAP-70 (IC$_{50}$ >100 µM). Inhibits the activation of focal adhesion kinase and its phosphorylation at Tyr^{577}. Also potently inhibits anti-CD3-stimulated tyrosine phosphorylation of human T cells (IC$_{50}$ = 600 nM). *Purity: ≥95% by HPLC.*

Ref.: Salazar, E.P., and Rozengurt, E. 1999. *J. Biol. Chem.* **274**, 28371; Hanke, J.H., et al. 1996. *J. Biol. Chem.* **271**, 695.

Please select your country: – Select Your Country –
Select your country to display pricing.

Size	In Stock	Qty	Price
1 mg	Y		N/A
Add to Cart	Add to My Product List		

* NOTE: In Stock status is based on item availability worldwide.

Solubility	Molecular Formula	Mol. Wt.
DMSO	$C_{15}H_{16}ClN_5$	301.8

Additional Categories:

❷ Protein Kinases » Protein Kinase Inhibitors » Protein Tyrosine Kinase (PTK) Inhibitors

---

AG Compounds: Inhibitory Effects on Protein Tyrosine Kinases (IC_{50} and/or K_i in µM)

Product	Alternate Name	Cat. No.	EGFR-K poly GAT	ErbB-2/neu (HER1-2)-K	PGDFR-K	trk	InsR-K	p60c-src-K	Comments	Ref.
AG 9	Tyrphostin A1	658390	>1250ᵃ						Negative control for other AG compounds.	1
AG 10	Tyrphostin A8	658475	560ᵃ						Inhibits GTPase activity of transducin (IC_{50} = 45 µM).	1,2
AG 17	Tyrphostin A9	658425	500ᵃ		0.5	>100			Selective inhibitor of PDGFR; uncouples oxidative phosphorylation.	1,3,4
AG 18	Tyrphostin A23	658395	40ᵃ		25	>100	4000		Potent broad range PTK inhibitor.	3,4
AG 30	Tyrphostin A30	121760						440	A potent protein tyrosine kinase inhibitor that exhibits greater specificity for c-ErbB.	5,6
AG 43	Tyrphostin A63	658450	6500ᵇ						Negative control for other AG compounds.	1
AG 82	Tyrphostin A25	658400	3ᵃ			>100		150	Most commonly-used AG compounds.	1,2,3
AG 99	Tyrphostin A46	658430	10ᵃ				410		Selective for EGFR over InsR.	1,7
AG 112	Tyrphostin A48	658440	0.125ᵃ			>100			Potent inhibitor of EGFR.	1
AG 126	Tyrphostin AC 126	658452	450ᵃ	>100	>100				Inhibitor of LPS-induced tyrosine phosphorylation of p42MAPK.	1,3,8
AG 183	Tyrphostin A51	658410	0.8ᵃ						Potent inhibitor of EGFR.	9
AG 213	Tyrphostin A47 (RC50864)	658405	2.4ᵃ		3	>100	640	8	Potent broad-range PTK inhibitor. Also inhibits PKC (IC_{50} = 60 µM).	9,10
AG 370	Tyrphostin AG 370	658454	>100ᵇ		25				Inhibits PDGF-induced mitogenesis in fibroblasts.	11
AG 490	Tyrphostin B42	658401	0.1ᵃ	13.5					Selective for EGFR over HER1-2. Also inhibits JAK-2.	7,9,12
AG 494	Tyrphostin B48	658407	1.24ᵃ	42	6		>100		Selective for EGFR over HER1-2.	7
AG 527	Tyrphostin B44(-)	658402	2.5ᵃ	37					Selective for EGFR over HER1-2.	7
AG 555	Tyrphostin B46	658404	0.7ᵃ	35			>100		Selective for EGFR over HER1-2.	7
AG 556	Tyrphostin B56	658415	5ᵃ	>500					Selective for EGFR over HER1-2.	7
AG 825	Tyrphostin AG 825	121765	19	0.35	40		>100		Highly selective for HER2-neu over EGFR.	13,14
AG 835	Tyrphostin B50	658409	0.86ᵃ						Positive enantiomer of AG 527.	7
AG 879	Tyrphostin AG 879	658460	>100ᵇ	1	>100	10			Selective inhibitor of p140c-trk.	15,16
AG 957	Tyrphostin AG 957	121761	0.25						Selectively blocks the tyrosine kinase activity of human p210bcr-abl (K_i = 0.75 µM) over p140bcr-abl (K_i = 10 µM).	17
AG 1288	Tyrphostin AG1288	658510	>100	>100	>100				Blocks TNFα induced cytotoxicity.	8
AG 1295	Tyrphostin AG1295	658550	>100ᵇ		0.5				Highly specific inhibitor of PDGFR.	13,18
AG 1296	Tyrphostin AG1296	658551	>100ᵇ,ᶜ	>100	1.0		>50		Highly specific inhibitor of PDGFR. Also inhibits FGF-induced proliferation (IC_{50} = 12 µM).	18
AG 1433	Tyrphostin AG1433	658553			5.0				Potent inhibitor of PDGF β-receptor kinase (IC_{50} = 5.0 µM) and KDR/Flk-1 (IC_{50} = 9.3 µM).	19,20
AG 1478	Tyrphostin AG1478	658552	0.003	>100	>100				Highly specific inhibitor of EGFR.	13
RG-1302		554725	1ᵇ,ᶜ						Shown to inhibit tumor growth in vivo.	21
RG-14620		554740	3ᵈ						Shown to inhibit tumor growth in vivo.	21
Bis-Tyrphostin		658418	0.4						Competitive inhibitor of the EGFR kinase.	4

References:
1. Gazit, A., et al. 1989. J. Med. Chem. 32, 2344.
2. Wolbring, G., et al. 1994. J. Biol. Chem. 269, 22470.
3. Bilder, C.E., et al. 1991. Am. J. Physiol. 260, C721.
4. Levitzki, A., and Gilon, S. 1991. Trends Pharmacol. Sci. 12, 171.
5. Wessely, O., et al. 1997. Cell Growth Differen. 8, 481.
6. Schwartz, B., et al. 1995. Oncol. Res. 7, 277
7. Gazit, A., et al. 1991. J. Med. Chem. 34, 1896.
8. Novogrodsky, A., et al. 1994. Science 264, 1319.

9. Levitzki, A. 1990. Biochem. Pharmacol. 40, 913.
10. Szende, B. et al. 1995. Cell Biol. Int. 19, 903.
11. Bryckaert, M.C., et al. 1992. Exp. Cell Res. 199, 255.
12. Meydan, N., et al. 1996. Nature 379, 645.
13. Levitzki, A., and Gazit, A. 1995. Science 267, 1782.
14. Osherov, N., et al. 1993. J. Biol. Chem. 268, 11134.
15. Ohmichi, M., et al. 1993. Biochemistry 32, 4650.
16. Konrad, R.J., et al. 1996. J. Biol. Chem. 271, 24179.
17. Anafi, M., et al. 1992. J. Biol. Chem. 267, 4518.

18. Kovalenko, M., et al. 1994. Cancer Res. 54, 6106.
19. Kroll, J., and Waltenberger, J. 1987. J. Biol. Chem. 272, 32521.
20. Strawn, L.M., et al. 1996. Cancer Res. 56, 3540.
21. Yoneda, T. et al. 1991. Cancer Res. 51, 4430.

a= measurement of phosphorylation of an exogenous substrate
b= in vivo autophosphorylation assay
c= in vitro autophosphorylation assay
d= EGF-dependent cell proliferation assay

Abbreviations:
EGFR K = Epidermal growth factor receptor kinase
HER 1-2-K = Chimera of erbB-2/neu kinase with the EGF binding domain
InsR-K = Insulin receptor kinase
PDGFR-K = Platelet-derived growth factor receptor kinase
p60src = Cellular homolog of src gene protein
PTK = Protein tyrosine kinase

Other Selected Protein Tyrosine Kinase Inhibitors

Inhibitor	Cat. No.	M.W.	Comments	Ref.
Aminogenistein	155100	253.3	Inhibits tyrosine kinase p56^{lck} phosphorylation of angiotensin I (IC$_{50}$ = 1.2 µM).	1
Butein	203987	272.3	A plant polyphenol that inhibits EGFR tyrosine kinase (IC$_{50}$ = 16 µM) and p60^{c-src} (IC$_{50}$ = 65 µM) activity.	2,3
Compound 32 (PD 153035)	234490	360.2	An extremely potent and specific inhibitor of the EGFR kinase (IC$_{50}$ = 25 pM; K$_i$ = 6 pM).	4,5
Compound 56	234505	388.3	The most potent and specific inhibitor of the EGFR kinase yet reported (IC$_{50}$ = 6 pM).	4
Daidzein	251600	254.2	Inactive analog of genistein.	6
Damnacanthal	251650	282.3	Potent and reversible inhibitor of p56^{lck} tyrosine kinase activity (IC$_{50}$ = 17 nM for p56^{lck} autophosphorylation and 620 nM for phosphorylation of an exogenous peptide). Does not significantly affect either PKA, PKC, or other tyrosine kinases.	7
Emodin	324694	270.2	Potent p56^{lck} tyrosine kinase inhibitor (IC$_{50}$ = 18.5 µM).	8
Erbstatin Analog	324930	194.2	Cell-permeable analog of erbstatin that inhibits the EGFR kinase (IC$_{50}$ = 780 nM) and is stable in solution for >60 minutes.	9
Geldanamycin	345805	560.6	A potent inhibitor of p60^{src} tyrosine kinase. Reported to destabilize mutated p53 protein from various cell lines.	10,11
Genistein	345834	270.2	Broad range tyrosine kinase inhibitor. Inhibits EGFR kinase (IC$_{50}$ = 2.6 µM) and p60^{v-src} (IC$_{50}$ = 25 µM). Inhibits Ser/Thr kinases, PKC, and PKA (IC$_{50}$ > 100 µM).	6
Herbimycin A	375670	574.7	Inhibits p60^{c-src} function (IC$_{50}$ = 900 µM) by irreversibly binding to the thiol groups of the kinase. Has known antitumor properties and has no significant effect on PKC or PKA activity.	12,13
HNMPA-(AM)$_3$	397100	454.4	Cell-permeable analog of HNMPA which yields the parent compound upon cleavage by cytosolic esterases. Inhibits insulin-stimulated glucose oxidation in intact cells (IC$_{50}$ = 10 µM).	14
Lavendustin A	428150	381.4	Potent inhibitor of EGFR kinase (IC$_{50}$ = 11 nM) and p60^{c-src} (IC$_{50}$ = 500 nM). Does not inhibit PKA or PKC at 100 µM.	15,16
Lavendustin B	428160	365.4	Inactive analog of lavendustin A. Inhibits the EGFR kinase (IC$_{50}$ = 1.3 µM).	16
Lavendustin C	234450	275.3	Potent inhibitor of p60^{c-src} (IC$_{50}$ = 500 nM). However, it also inhibits Ca^{2+}/calmodulin kinase II (IC$_{50}$ = 200 nM).	15
Lavendustin C Methyl Ester	234455	289.3	Inhibits EGFR kinase phosphorylation of RRSrc peptide (IC$_{50}$ = 600 nM).	17
Leflunomide	429600	270.2	Immunosuppressive agent acts as an inhibitor of p56^{lck}, p56^{lyn}, JAK3, and EGFR kinase.	18
Piceatannol	527948	244.2	A plant metabolite. Preferentially inhibits the activity of Syk (IC$_{50}$ = 10 µM), a non-receptor tyrosine kinase, over Lyn in isolated enzyme preparations.	19
PP2	529573	301.8	Potent and selective inhibitor of src family of tyrosine kinases. Inhibits p56^{lck} (IC$_{50}$ = 4 nM), p59^{fyn} (IC$_{50}$ = 5 nM), and Hck (IC$_{50}$ = 5 nM). Does not affect the activity of EGFR kinase, JAK2, or ZAP-70 at these levels.	20
PP3	529574	211.2	A negative control for src family tyrosine kinase inhibitor PP2. However, it inhibits the activity of EGF receptor kinase (IC$_{50}$ = 2.7 µM).	21
Radicicol, *Diheterospora chlamydosporia*	553400	364.8	Antifungal macrocyclic lactone that inhibits p60^{v-src} kinase activity (IC$_{50}$ = 8.2 µM). Inhibits the expression of mitogen-inducible COX-2 (IC$_{50}$ = 27 nM) without affecting COX-1 expression in LPS-stimulated macrophages.	22,23
ST 638	567790	354.4	Inhibits phospholipase D activity in human neutrophils at a site between the receptor and the phospholipase.	24
SU1498	572888	390.5	A potent and selective inhibitor of Flk-1 kinase (VEGFR kinase) that exhibits only a weak inhibitor effect on PDGFR, EGFR, and HER-2 kinases.	25
SU4984	572625	333.4	Inhibits tyrosine kinase activity of the fibroblast growth factor receptor 1 (IC$_{50}$ = 10 - 20 µM in the presence of 1 mM ATP). Reported to inhibit PDGF receptor and insulin receptor phosphorylation. Also inhibits aFGF-induced phosphorylation of ERK1 and ERK2 (IC$_{50}$ = 20 - 40 µM). Does not inhibit the kinase activity of EGF receptor.	26
SU5402	572630	296.3	Inhibits the tyrosine kinase activity of the fibroblast growth factor receptor 1 (IC$_{50}$ = 10 - 20 µM in the presence of 1 nM ATP). Acts as a weak inhibitor of PDGF receptor phosphorylation and does not inhibit the phosphorylation of insulin receptor. Also inhibits aFGF-induced phosphorylation of ERK1 and ERK2 (IC$_{50}$ = 10 - 20 µM). Does not inhibit the kinase activity of EGF receptor.	26
SU5614	572632	272.7	A potent inhibitor of VEGF (Flk-1) (IC$_{50}$ = 1.2 µM) and PDGF (IC$_{50}$ = 2.9 µM) receptor tyrosine kinases. Does not affect EGF and IGF receptor tyrosine kinases.	27
Psi-tectorigenin	540100	300.3	Inhibits EGR receptor tyrosine kinase activity (IC$_{50}$ = 3.3 µM). Also inhibits EGF-induced Ca^{2+} release and phosphatidylinositol turnover.	28,29
Tyrosine-Specific Protein Kinase Inhibitor	657015	2482.7	Peptide corresponding to the non-catalytic domain of p60^{v-src} (137-157). Inhibits p60^{v-src} (IC$_{50}$ = 7.5 µM) and EGFR kinase but does not significantly inhibit PKA or PKC even at 100 µM.	30

References:
1. Cushman, M. et al. 1991. *J. Med. Chem.* 34, 798.
2. Chan, S.C. et al. 1996. *Science* 265, 1093.
3. Yang, E.B. et al. 1998. *Biochem. Biophys. Res. Commun.* 245, 435.
4. Bridges, A.J. et al. 1996. *J. Med. Chem.* 39, 267.
5. Fry, D.W. et al. 1994. *Science* 265, 1093.
6. Akiyama, T. et al. 1987. *J. Biol. Chem.* 262, 5592.

7. Faltynek, C.R. et al. 1995. *Biochemistry* 34, 12404.
8. Umezawa, K. et al. 1990. *FEBS Lett.* 260, 198.
9. Chan, T.C.K. et al. 1993. *Biochem. Biophys. Res. Commun.* 193, 1152.
10. Blagosklonny, M.V. et al. 1995. *Oncogene* 11, 933.
11. Yamaki, H. et al. 1989. *J. Antibiot.* 42, 604.
12. Uehara, Y. et al. 1986. *J. Biol. Chem.* 271, 895.
13. Fukazawa, H. et al. 1991. *Biochem. Pharmacol.* 42, 1661.

14. Saperstein, R. et al. 1989. *Biochemistry* 28, 5694.
15. O'Dell, T.J. et al. 1991. *Nature* 353, 558.
16. Onoda, T. et al. 1989. *J. Nat. Prod.* 52, 1252.
17. Chen, H. et al. 1993. *J. Med. Chem.* 36, 4094.
18. Xu, X. et al. 1995. *J. Biol.Chem.* 270, 12399.
19. Oliver, J.M. et al. 1994. *J. Biol. Chem.* 269, 29697.
20. Hanke, J.H. et al. 1996. *J. Biol. Chem.* 271, 695.
21. Traxler, P. et al. 1997. *J. Med. Chem.* 40, 3601.
22. Yen, A. et al. 1994. *Exp. Cell Res.* 214, 163.

23. Kwon, H.J. et al. 1992. *Cancer Res.* 52, 6926.
24. Uings, I. et al. 1992. *Biochem. J.* 281, 597.
25. Strawn, L.M. et al. 1996. *Cancer Res.* 56, 3540.
26. Mohammadi, M. et al. 1997. *Science* 276, 955.
27. Sun, L. et al. 1998. *215th ACS Meeting, Dallas, Poster* 167.
28. Hlmpens, B. et al. 1994. *FASEB J.* 8, 879.
29. Imoto, M. et al. 1991. *J. Cell Pharmacol.* 2, 40.
30. Sato, K. et al. 1990. *Biochem. Biophys. Res. Commun.* 171, 1152.

SEQUENCE LISTING

<110> Hirsch, Alec

     Nelson, Jay

     Früh, Klaus

     DeFillipis, Victor

     King, Jeff

<120>   INHIBITION OF FLAVIVIRUS REPLICATION BY INHIBITORS OF SRC-FAMILY KINASES

<130>   49321-97

<160>   4

<170>   PatentIn version 3.1

<210>   1

<211>   21

<212>   RNA

<213>   Homo sapiens

<400>   1
aacgccuuuu ggaggugcau c   21

<210>   2

<211>   21

<212>   RNA

<213>   Homo sapiens

<400>   2
aagcuagaac uacagaagac c   21

<210> 3

<211> 4343

<212> RNA

<213> Homo sapiens

<220>

<221> CDS

<222> (11)..(1639)

<223>

<400> 3
agauuugaua aug ggc ugc auu aaa agu aaa gaa aac aaa agu cca gcc   49
          Met Gly Cys Ile Lys Ser Lys Glu Asn Lys Ser Pro Ala
          1   5   10

auu aaa uac aga ccu gaa aau acu cca gag ccu guc agu aca agu gug   97
Ile Lys Tyr Arg Pro Glu Asn Thr Pro Glu Pro Val Ser Thr Ser Val
   15   20   25

agc cau uau gga gca gaa ccc acu aca gug uca cca ugu ccg uca ucu   145
Ser His Tyr Gly Ala Glu Pro Thr Thr Val Ser Pro Cys Pro Ser Ser
30   35   40   45

uca gca aag gga aca gca guu aau uuc agc agu cuu ucc aug aca cca   193
Ser Ala Lys Gly Thr Ala Val Asn Phe Ser Ser Leu Ser Met Thr Pro
          50   55   60

uuu gga gga ucc uca ggg gua acg ccu uuu gga ggu gca ucu ucc uca   241
Phe Gly Gly Ser Ser Gly Val Thr Pro Phe Gly Gly Ala Ser Ser Ser
             65   70   75

uuu uca gug gug cca agu uca uau ccu gcu ggu uua aca ggu ggu guu   289
Phe Ser Val Val Pro Ser Ser Tyr Pro Ala Gly Leu Thr Gly Gly Val
        80   85   90

acu aua uuu gug gcc uua uau gau uau gaa gcu aga acu aca gaa gac   337
Thr Ile Phe Val Ala Leu Tyr Asp Tyr Glu Ala Arg Thr Thr Glu Asp
   95   100   105

cuu uca uuu aag aag ggu gaa aga uuu caa aua auu aac aau acg gaa   385
Leu Ser Phe Lys Lys Gly Glu Arg Phe Gln Ile Ile Asn Asn Thr Glu
110   115   120   125

gga gau ugg ugg gaa gca aga uca auc gcu aca gga aag aau ggu uau   433
Gly Asp Trp Trp Glu Ala Arg Ser Ile Ala Thr Gly Lys Asn Gly Tyr
          130   135   140

auc ccg agc aau uau gua gcg ccu gca gau ucc auu cag gca gaa gaa   481

Page 2

```
Ile Pro Ser Asn Tyr Val Ala Pro Ala Asp Ser Ile Gln Ala Glu Glu
        145             150             155
```

```
ugg uau uuu ggc aaa aug ggg aga aaa gau gcu gaa aga uua cuu uug    529
Trp Tyr Phe Gly Lys Met Gly Arg Lys Asp Ala Glu Arg Leu Leu Leu
        160             165             170
```

```
aau ccu gga aau caa cga ggu auu uuc uua gua aga gag agu gaa aca    577
Asn Pro Gly Asn Gln Arg Gly Ile Phe Leu Val Arg Glu Ser Glu Thr
        175             180             185
```

```
acu aaa ggu gcu uau ucc cuu ucu auu cgu gau ugg gau gag aua agg    625
Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp Asp Glu Ile Arg
190             195             200             205
```

```
ggu gac aau gug aaa cac uac aaa auu agg aaa cuu gac aau ggu gga    673
Gly Asp Asn Val Lys His Tyr Lys Ile Arg Lys Leu Asp Asn Gly Gly
                210             215             220
```

```
uac uau auc aca acc aga gca caa uuu gau acu cug cag aaa uug gug    721
Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Asp Thr Leu Gln Lys Leu Val
            225             230             235
```

```
aaa cac uac aca gaa cau gcu gau ggu uua ugc cac aag uug aca acu    769
Lys His Tyr Thr Glu His Ala Asp Gly Leu Cys His Lys Leu Thr Thr
        240             245             250
```

```
gug ugu cca acu gug aaa ccu cag acu caa ggu cua gca aaa gau gcu    817
Val Cys Pro Thr Val Lys Pro Gln Thr Gln Gly Leu Ala Lys Asp Ala
        255             260             265
```

```
ugg gaa auc ccu cga gaa ucu uug cga cua gag guu aaa cua gga caa    865
Trp Glu Ile Pro Arg Glu Ser Leu Arg Leu Glu Val Lys Leu Gly Gln
270             275             280             285
```

```
gga ugu uuc ggc gaa gug ugg aug gga aca ugg aau gga acc acg aaa    913
Gly Cys Phe Gly Glu Val Trp Met Gly Thr Trp Asn Gly Thr Thr Lys
                290             295             300
```

```
gua gca auc aaa aca cua aaa cca ggu aca aug aug cca gaa gcu uuc    961
Val Ala Ile Lys Thr Leu Lys Pro Gly Thr Met Met Pro Glu Ala Phe
            305             310             315
```

```
cuu caa gaa gcu cag aua aug aaa aaa uua aga cau gau aaa cuu guu    1009
Leu Gln Glu Ala Gln Ile Met Lys Lys Leu Arg His Asp Lys Leu Val
        320             325             330
```

```
cca cua uau gcu guu guu ucu gaa gaa cca auu uac auu guc acu gaa    1057
Pro Leu Tyr Ala Val Val Ser Glu Glu Pro Ile Tyr Ile Val Thr Glu
        335             340             345
```

```
uuu aug uca aaa gga agc uua uua gau uuc cuu aag gaa gga gau gga    1105
Phe Met Ser Lys Gly Ser Leu Leu Asp Phe Leu Lys Glu Gly Asp Gly
350             355             360             365
```

```
aag uau uug aag cuu cca cag cug guu gau aug gcu gcu cag auu gcu    1153
Lys Tyr Leu Lys Leu Pro Gln Leu Val Asp Met Ala Ala Gln Ile Ala
            370             375             380
```

Page 3

```
gau ggu aug gca uau auu gaa aga aug aac uau auu cac cga gau cuu     1201
Asp Gly Met Ala Tyr Ile Glu Arg Met Asn Tyr Ile His Arg Asp Leu
            385                 390                 395

cgg gcu gcu aau auu cuu gua gga gaa aau cuu gug ugc aaa aua gca     1249
Arg Ala Ala Asn Ile Leu Val Gly Glu Asn Leu Val Cys Lys Ile Ala
            400                 405                 410

gac uuu ggu uua gca agg uua auu gaa gac aau gaa uac aca gca aga     1297
Asp Phe Gly Leu Ala Arg Leu Ile Glu Asp Asn Glu Tyr Thr Ala Arg
            415                 420                 425

caa ggu gca aaa uuu cca auc aaa ugg aca gcu ccu gaa gcu gca cug     1345
Gln Gly Ala Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ala Ala Leu
430                 435                 440                 445

uau ggu cgg uuu aca aua aag ucu gau guc ugg uca uuu gga auu cug     1393
Tyr Gly Arg Phe Thr Ile Lys Ser Asp Val Trp Ser Phe Gly Ile Leu
                450                 455                 460

caa aca gaa cua gua aca aag ggc cga gug cca uau cca ggu aug gug     1441
Gln Thr Glu Leu Val Thr Lys Gly Arg Val Pro Tyr Pro Gly Met Val
                465                 470                 475

aac cgu gaa gua cua gaa caa gug gag cga gga uac agg aug ccg ugc     1489
Asn Arg Glu Val Leu Glu Gln Val Glu Arg Gly Tyr Arg Met Pro Cys
            480                 485                 490

ccu cag ggc ugu cca gaa ucc cuc cau gaa uug aug aau cug ugu ugg     1537
Pro Gln Gly Cys Pro Glu Ser Leu His Glu Leu Met Asn Leu Cys Trp
            495                 500                 505

aag aag gac ccu gau gaa aga cca aca uuu gaa uau auu cag ucc uuc     1585
Lys Lys Asp Pro Asp Glu Arg Pro Thr Phe Glu Tyr Ile Gln Ser Phe
510                 515                 520                 525

uug gaa gac uac uuc acu gcu aca gag cca cag uac cag cca gga gaa     1633
Leu Glu Asp Tyr Phe Thr Ala Thr Glu Pro Gln Tyr Gln Pro Gly Glu
                530                 535                 540

aau uua uaauucaagu agccauuuuu auaugcacaa aucugccaaa auauaaagaa     1689
Asn Leu

cuuguguaga uuuucuacag gaaucaaaag aagaaaaucu ucuuuacucu gcauguuuuu     1749

aaugguaaac uggaauccca gauaugguug cacaaaacca cuuuuuuuuc cccaaguauu     1809

aaacucuaau guaccaauga ugaauuuauc agcguauuuc aggguccaaa caaaauagag     1869

cuaagauacu gaugacagug ugggugacag cauggguaug aaggacagug aggcuccugc     1929

uuauuuauaa aucauuuccu uucuuuuuuu ccccaaaguc agaauugcuc aaagaaaauu     1989

auuuauuguu acagauaaaa cuugagagau aaaaagcuau accauaauaa aaucuaaaau     2049

uaaggaauau cauggggacca aauaauucca uuccaguuuu uuaaaguuuc uugcauuuau     2109

uauucucaaa aguuuuuucu aaguuaaaca gucaguaugc aaucuuaaua uaugcuuucu     2169
```

Page 4

uuugcaugga caugggccag guuuuucaaa aggaauauaa acaggaucuc aaacuugauu   2229

aaauguuaga ccacagaagu ggaauuugaa aguauaaugc aguacauuaa uauucauguu   2289

cauggaacug aaagaauaag aacuuuuuca cuucaguccu uuucugaaga guuugacuua   2349

gaauaaugaa gguaacuaga aagugaguua aucuuguaug agguugcauu gauuuuuuaa   2409

ggcaauauau aauugaaacu acuguccaau caaaggggaa auguuuugau cuuuagauag   2469

caugcaaagu aagacccagc auuuuaaaag cccuuuuuaa aaacuagacu ucguacugug   2529

aguauugcuu auauguccuu auggggaugg gugccacaaa uagaaaauau gaccagauca   2589

gggacuugaa ugcacuuuug cucaugguga auauagauga acagagagga aaauguauuu   2649

aaaagaaaua cgagaaaaga aaaugugaaa guuuuacaag uuagagggau ggaagguaau   2709

guuuaauguu gaugucaugg agugacagaa uggcuuugcu ggcacucaga gcuccucacu   2769

uagcuauauu cugagacuuu gaagaguuau aaaguauaac uauaaaacua auuuuucuua   2829

cacacuaaau ggguauuugu ucaaaauaau gaaguuaugg cuucacauuc auugcagugg   2889

gauaugguuu uuauguaaaa cauuuuuaga acuccaguuu ucaaaucaug uuugaaucua   2949

cauucacuuu uuuuuguuuu cuuuuuugag acggagucuc gcucugccgc ccaggcugga   3009

gugcagugge gcgaucucgg cucacugcaa gcucugccuc ccagguucac accauucucc   3069

ugccucagcc ucccgaguag cugggacuac aggugcccac caccacgccu ggcuaguuuu   3129

uuguauuuuu aguagagacg caguuucacc guguuagcca ggauggucuc gaucuccuga   3189

ccuugugauc ugcccgccuc ggccucccaa agugcuggga uuacaggcgu gagccaccgc   3249

gcccagccua cauucacuuc uaaagucuau guaaugguggg ucauuuuuuc ccuuuuagaa   3309

uacauuaaau gguugauuug gggaggaaaa cuuauucuga auauuaacgg uggugaaaag   3369

gggacaguuu uuacccuaaa gugcaaaagu gaaacauaca aaauaagacu aauuuuuaag   3429

aguaacucag uaauuucaaa auacagauuu gaauagcagc auuagugguu ugagugucua   3489

gcaaaggaaa aauugaugaa uaaaaugaag gucuggugua uauguuuuaa aauacucuca   3549

uauagucaca cuuuaaauua agccuuauau uaggccccuc uauuuucagg auauaauucu   3609

uaacuaucau uauuuaccug auuuuaauca ucagauucga aauucugugc cauggcguau   3669

auguucaaau ucaaaccauu uuuaaaaugu gaagauggac uucaugcaag uuggcagugg   3729

uucugguacu aaaaauugug guuguuuuuu cuguuuacgu aaccugcuua guauugacac   3789

ucucuaccaa gagggucuuc cuaagaagag ugcugucauu auuuccucuu aucaacaacu   3849

ugugacauga gauuuuuuaa gggcuuuaug ugaacuauga uauuguaauu uuucuaagca   3909

uauucaaaag gguagacaaaa uuacguuuau guacuaaauc uaaucaggaa aguaaggcag   3969

gaaaaguuga ugguauucau uagguuuuaa cugaauggag caguuccuua uauaauaaca   4029

auuguauagu agggauaaaa cacuaacuua auguguauuc auuuuaaauu guucuguauu   4089

uuuaaauugc caagaaaaac aacuuuguaa auuuggagau auuuuccaac agcuuuucgu   4149

cuucaguguc uuaaugugga aguuaacccu uaccaaaaaa ggaaguuggc aaaaacagcc   4209

uucuagcaca cuuuuuuaaa ugaauaaugg uagccuaaac uuaauauuuu uauaaaguau   4269

uguaauauug uuuuguggau aauugaaaua aaaaguucuc auugaaugca ccuauuaaaa   4329

aaaaaaaaaa aaaa   4343

<210> 4

<211> 543

<212> PRT

<213> Homo sapiens

<400> 4

Met Gly Cys Ile Lys Ser Lys Glu Asn Lys Ser Pro Ala Ile Lys Tyr
1   5   10   15

Arg Pro Glu Asn Thr Pro Glu Pro Val Ser Thr Ser Val Ser His Tyr
                20   25   30

Gly Ala Glu Pro Thr Thr Val Ser Pro Cys Pro Ser Ser Ser Ala Lys
            35   40   45

Gly Thr Ala Val Asn Phe Ser Ser Leu Ser Met Thr Pro Phe Gly Gly
        50   55   60

Ser Ser Gly Val Thr Pro Phe Gly Gly Ala Ser Ser Ser Phe Ser Val
65   70   75   80

Val Pro Ser Ser Tyr Pro Ala Gly Leu Thr Gly Gly Val Thr Ile Phe
                85   90   95

Val Ala Leu Tyr Asp Tyr Glu Ala Arg Thr Thr Glu Asp Leu Ser Phe
            100   105   110

Lys Lys Gly Glu Arg Phe Gln Ile Ile Asn Asn Thr Glu Gly Asp Trp
            115   120   125

Page 6

Trp Glu Ala Arg Ser Ile Ala Thr Gly Lys Asn Gly Tyr Ile Pro Ser
    130   135   140

Asn Tyr Val Ala Pro Ala Asp Ser Ile Gln Ala Glu Glu Trp Tyr Phe
145   150   155   160

Gly Lys Met Gly Arg Lys Asp Ala Glu Arg Leu Leu Leu Asn Pro Gly
                165   170   175

Asn Gln Arg Gly Ile Phe Leu Val Arg Glu Ser Glu Thr Thr Lys Gly
            180   185   190

Ala Tyr Ser Leu Ser Ile Arg Asp Trp Asp Glu Ile Arg Gly Asp Asn
        195   200   205

Val Lys His Tyr Lys Ile Arg Lys Leu Asp Asn Gly Gly Tyr Tyr Ile
    210   215   220

Thr Thr Arg Ala Gln Phe Asp Thr Leu Gln Lys Leu Val Lys His Tyr
225   230   235   240

Thr Glu His Ala Asp Gly Leu Cys His Lys Leu Thr Thr Val Cys Pro
                245   250   255

Thr Val Lys Pro Gln Thr Gln Gly Leu Ala Lys Asp Ala Trp Glu Ile
                260   265   270

Pro Arg Glu Ser Leu Arg Leu Glu Val Lys Leu Gly Gln Gly Cys Phe
        275   280   285

Gly Glu Val Trp Met Gly Thr Trp Asn Gly Thr Thr Lys Val Ala Ile
    290   295   300

Lys Thr Leu Lys Pro Gly Thr Met Met Pro Glu Ala Phe Leu Gln Glu
305   310   315   320

Ala Gln Ile Met Lys Lys Leu Arg His Asp Lys Leu Val Pro Leu Tyr
            325   330   335

Ala Val Val Ser Glu Glu Pro Ile Tyr Ile Val Thr Glu Phe Met Ser
            340   345   350

Lys Gly Ser Leu Leu Asp Phe Leu Lys Glu Gly Asp Gly Lys Tyr Leu

```
                     355                      360                       365
```

Lys Leu Pro Gln Leu Val Asp Met Ala Ala Gln Ile Ala Asp Gly Met
    370   375   380

Ala Tyr Ile Glu Arg Met Asn Tyr Ile His Arg Asp Leu Arg Ala Ala
385   390   395   400

Asn Ile Leu Val Gly Glu Asn Leu Val Cys Lys Ile Ala Asp Phe Gly
                405   410   415

Leu Ala Arg Leu Ile Glu Asp Asn Glu Tyr Thr Ala Arg Gln Gly Ala
            420   425   430

Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ala Ala Leu Tyr Gly Arg
        435   440   445

Phe Thr Ile Lys Ser Asp Val Trp Ser Phe Gly Ile Leu Gln Thr Glu
    450   455   460

Leu Val Thr Lys Gly Arg Val Pro Tyr Pro Gly Met Val Asn Arg Glu
465   470   475   480

Val Leu Glu Gln Val Glu Arg Gly Tyr Arg Met Pro Cys Pro Gln Gly
                485   490   495

Cys Pro Glu Ser Leu His Glu Leu Met Asn Leu Cys Trp Lys Lys Asp
                500   505   510

Pro Asp Glu Arg Pro Thr Phe Glu Tyr Ile Gln Ser Phe Leu Glu Asp
        515   520   525

Tyr Phe Thr Ala Thr Glu Pro Gln Tyr Gln Pro Gly Glu Asn Leu
    530   535   540